Navigation Links
An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market
Date:6/23/2009

Emerging Combination Products from GlaxoSmithKline/Theravance, Boehringer Ingelheim and Novartis Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a 28 percent increase in the diagnosed prevalent population will drive growth in the chronic obstructive pulmonary disease (COPD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Despite market constraints that include currently low diagnosis rates, pricing and reimbursement restrictions and challenging regulatory landscapes, the COPD drug market will grow by nearly $4.3 billion from 2008 to 2018.

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that maintenance therapies dominated the COPD market in 2008 as nearly 80 percent of COPD sales were generated by such agents. Although safety concerns are associated with several maintenance therapies commonly prescribed for COPD, including ICS-containing products as well as inhaled anticholinergics, physicians indicate that they will continue to widely prescribe these drugs to their COPD patients but will remain vigilant in monitoring the safety of these drugs in their patients who receive them. The report finds that as new long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA products emerge from clinical development over the next decade, the use of maintenance therapies will continue to increase.

Several once-daily dosed LABAs such as Novartis's indacaterol, Boehringer Ingelheim's BI-1744-CL and GlaxoSmithKline/Theravance's GW-642444 will also enter the COPD market over the next decade. The report finds that these emerging once-daily LABAs will be the cornerstones of combinatio
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. U.S. Army Increases Medical and Dental School Benefits
2. A 50% Increase in Medical Bankruptcies - A Worry for Adults Assisting Aging Parents
3. Winner Medical to Benefit From the Increase of Tax Rebate Rate for Exports From China
4. Hodgkin lymphoma survivors have increased risk of stroke and transient ischemic attack
5. No Matter the Vehicle, Sending Text Messages While Driving Increases Risk of Accidents, Warns New York Auto Accident Lawyer
6. Hartford grants increase support for geriatric social work training
7. Study Shows Increases in Working After 65 and Using Commercial Insurance
8. Depression may increase Alzheimers risk in people with memory problems
9. Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
10. Colonoscopy Risks Increase With Age and Illness
11. For Men Over 50, Odds of Eye Discomfort Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... 2014, Insight Product Development has effectively doubled the size of its annual health ... Midwest medical device and digital health startups to compete for cash and prizes ...
(Date:9/4/2015)... Viejo, CA (PRWEB) , ... September 04, 2015 , ... ... click of a mouse all within Final Cut Pro X. With TransCel users have ... Adjust the frame width, background color, speed method, frame color, inner color, text, and ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed ... Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, has ... Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have ...
(Date:9/4/2015)... ... 2015 , ... The Providence Fertility Center will host a Fertility Cocktail Hour" ... freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and lounge, ... event will discuss the basics of female fertility and egg freezing, and offer women ...
Breaking Medicine News(10 mins):Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2
... included nearly 57,000 women who had been followed for ... -- Hormone therapy may lower a woman,s risk of ... the hormones. , This new finding, published in the ... , further complicates an already murky picture of the ...
... SANTA CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... today that the,Company will report fourth quarter and fiscal ... the close of market. Financial results will,be released over ... on the,Investor Relations section of the Company,s website at, ...
... Calif., Jan. 8 TEAC America, Inc. launches its,next ... dye-sublimation disc printer available, during the CES Show at,the ... The P-55C printer can be integrated ... Discathlon 2. With TEAC,s,AL220S and AL550S, customers can ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... officer. Formerly president and chief operating officer,Popovits is ... In addition, G.,Bradley Cole has been appointed as chief ... chief financial officer, reporting to Popovits. , ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
Cached Medicine News:Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
(Date:9/4/2015)... 2015  Pharmaceutical companies today rely heavily on ... Specialists (FBMS) to build and strengthen vital relationships ... in critical therapeutic areas. To ... are expanding the critical MSL function into global ... objectives and to achieve regional consistency, compliance, and ...
(Date:9/4/2015)... , Sept. 4, 2015  Dohmen Company CEO ... the Metropolitan Milwaukee Association of Commerce,s annual ,Future 50, ... the Pfister Hotel. The ,Future 50, Awards highlights the ... and young firms headquartered in the seven-county ... called Milwaukee home for more ...
Breaking Medicine Technology:Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2
... ... 7 , Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) and ... of positive data from a phase 1 study of TRU-016 in ... 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a ...
... , HOBOKEN, N.J., Dec. 7 ... the U.S. Food and Drug Administration has approved ... in patients with all types of von Willebrand disease (VWD). Wilate® ... Factor VIII Concentrate (Human) that demonstrated efficacy for all types of ...
Cached Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Medicine Products: